Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol–Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory disease associated with the high morbidity and mortality. Long-term intermittent therapy by inhalable antibiotics has recently emerged as an effective approach for NCFB treatment. However, the effective delivery of antibiotics to the lung requires administering a high dose to the site of infection. Herein, we investigated the novel inhalable silk-based microparticles as a promising approach to deliver high-payload ciprofloxacin (CIP) for NCFB therapy. Silk fibroin (SF) was applied to improve drug-payload and deposit efficiency of the dry powder particles. Mannitol was added as a mucokinetic agent. The dry powder inhaler (DPI) formulations of CIP microparticles were evaluated in vitro in terms of the aerodynamic performance, particle size distribution, drug loading, morphology, and their solid state. The optimal formulation (highest drug loading, 80%) exhibited superior aerosolization performance in terms of fine particle fraction (45.04 ± 0.84%), emitted dose (98.10 ± 1.27%), mass median aerodynamic diameter (3.75 ± 0.03 μm), and geometric standard deviation (1.66 ± 0.10). The improved drug loading was due to the electrostatic interactions between the SF and CIP by adsorption, and the superior aerosolization efficiency would be largely attributed to the fluffy and porous cotton-like property and low-density structure of SF. The presented results indicated the novel inhalable silk-based DPI microparticles of CIP could provide a promising strategy for the treatment of NCFB.
KEY WORDSdry powder inhaler silk fibroin bronchiectasis antibiotic ciprofloxacin
This work was supported by National Natural Science Foundation of China (Grant No. 81503001), Guangdong Natural Science Foundation (Grant No. 2016A030313330), Guangdong Province Science and Technology Plan Project Public Welfare Fund and Ability Construction Project (Grant No. 2017A020215081, Grant No. 2016A020215069, Grant No. 2016A020215063), the Science and Technology Foundation of Guangzhou (Grant No.201707010103), and Yixian Scientific Research Project Set Sail (Grant No. YXQH201706).
- 1.Polverino E, Dimakou K, Hurst J, Angel Martinez-Garcia M, Miravitlles M, Paggiaro P, et al. The overlap between bronchiectasis and chronic airways diseases: state of the art and future directions. Eur Respir J. 2018;52:1800328. https://doi.org/10.1183/13993003.00328-2018.CrossRefPubMedGoogle Scholar
- 6.Ungaro F, d’Angelo I, Coletta C, d’Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release. 2012;157:149–59.CrossRefGoogle Scholar
- 8.Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014;2:738–49.CrossRefGoogle Scholar
- 11.De Soyza A, Aksamit T, Bandel T-J, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702052. https://doi.org/10.1183/13993003.02052-2017.CrossRefPubMedGoogle Scholar
- 12.Aksamit T, De Soyza A, Bandel T-J, Criollo M, Elborn JS, Operschall E, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51:1702053. https://doi.org/10.1183/13993003.02053-2017.CrossRefPubMedGoogle Scholar
- 13.Haworth C, Wanner A, Froehlich J, O’Neal T, Davis A, Gonda I, et al. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa infection. J Aerosol Med Pulm Drug Deliv. 2017;30:29.Google Scholar
- 35.Sahoo S, Chakraborti CK, Mishra SC, Nanda UN, Naik S. FTIR and XRD investigations of some fluoroquinolones. Int J Pharm Pharm Sci. 2011;3:165–70.Google Scholar